![]() | |
Company type | Subsidiary |
---|---|
Nasdaq: CELG | |
Industry | Biotechnology |
Founded | 1986 |
Founder | Sol J. Barer |
Headquarters | Summit, New Jersey, U.S. |
Key people | Robert J. Hugin (executive chairman) Mark Alles (CEO) |
Products | Revlimid Abraxane Pomalyst/Imnovid Thalomid Idhifa |
Revenue | ![]() |
![]() | |
Total assets | ![]() |
Total equity | ![]() |
Number of employees | 8,852 (2018) |
Parent | Bristol Myers Squibb |
Website | www |
Footnotes / references [1] |
Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).[2]